Vitrectomy

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

Retrieved on: 
Tuesday, March 26, 2024
Partnership, Patient, CNS, Ophthalmology, Quality of life, Vitrectomy, Pharmaceutical industry

"We are thrilled to announce a new licensing deal that we believe will make our product available to more patients undergoing the tedious Vitrectomy procedure.

Key Points: 
  • "We are thrilled to announce a new licensing deal that we believe will make our product available to more patients undergoing the tedious Vitrectomy procedure.
  • With this new licensing agreement in place, ABVC will continue to serve as the R&D partner of ForSeeCon to discover new pipelines for ophthalmic products.
  • ABVC will receive the first licensing payment of US$30,000,000 (cash/shares) within 30 days after executing the agreement.
  • ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707

Global Retinal Surgery Devices Markets Forecast to 2030 - Company Profiles, Major Deals, Strategy and Recent Developments, Featuring Alcon, Carl Zeiss Meditec, Iridex, Lumenis, Optos & Nidek - ResearchAndMarkets.com

Retrieved on: 
Friday, February 16, 2024
Optical, Health, Surgery, Medical Devices, Therapy, Diabetic retinopathy, Incidence, Retina, Retinal detachment, Growth, Prevalence, Instrument, Diabetes, Disease, Paratriathlon, Retinal, Vitrectomy, Dentistry

The "Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Company Profiles, Major Deals, Strategy and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Company Profiles, Major Deals, Strategy and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global retinal surgery devices market is projected to reach US$ 4.71 Billion by 2030.
  • The global retinal surgery devices market is mainly driven by the increasing prevalence of ophthalmic conditions, especially diabetic retinopathy.
  • This report has been analyzed from 8 viewpoints:
    Global Retinal Surgery Devices Market - Company Profiles, Major Deals, Strategy, Sales, Recent Developments

Harrow Completes Transfer of the TRIESENCE® New Drug Application

Retrieved on: 
Wednesday, November 29, 2023
Health, FDA, Surgery, Clinical Trials, Pharmaceutical, Optical, Biotechnology, NDA, Marketing, New Drug Application, Uveitis, Vitrectomy, Giant cell arteritis, Acquisition, Pharmaceutical industry

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy.

Key Points: 
  • Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy.
  • In January of 2023, Harrow agreed to acquire the U.S. commercial rights to TRIESENCE.
  • Aside from the transfer of the TRIESENCE NDA ahead of the date previously agreed to, all other acquisition terms remain unchanged.
  • We remain excited to be able to provide TRIESENCE to the U.S. ophthalmic community soon.”

Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression

Retrieved on: 
Tuesday, July 11, 2023
Royal Adelaide Hospital, MBBS, Cataract, Clinical trial, Retinitis pigmentosa, Vitrectomy, Paratriathlon, Oxidative stress, Doctor of Philosophy, Eye, Patient, RAH, Growth, GLARE, Safety, Pharmaceutical industry, Honours degree

FORT WORTH, Texas, July 11, 2023 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced that a clinical trial site has been added to its Phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.

Key Points: 
  • FORT WORTH, Texas, July 11, 2023 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced that a clinical trial site has been added to its Phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.
  • Promising safety signals have been observed in the initial subjects.
  • “With two of our lead candidates advancing through clinical proof-of-concept trials, this is a pivotal time of progress and growth for Nacuity,” said Halden Conner, Chairman, CEO, and Co-Founder of Nacuity Pharmaceuticals.
  • “Our clinical programs are focused on treating retinitis pigmentosa and other eye diseases in which oxidative stress plays a significant role, including cataracts.

Global Diabetic Retinopathy Market Report 2023: Sector is Expected to Reach $13.77 Billion by 2030 at a CAGR of 6.4% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 4, 2023
Health, Diabetes, Aging of the United States, Visual impairment, Patellar tendon rupture, Laser surgery, COVID-19, Population Reference Bureau, Intravitreal injection, Diabetic retinopathy, International Diabetes Federation, Paratriathlon, USD, Incidence, Ageing, Management, Pharmaceutical industry, Vitrectomy

The global diabetic retinopathy market size is expected to reach USD 13.77 billion by 2030 registering a CAGR of 6.4% from 2023 to 2030.

Key Points: 
  • The global diabetic retinopathy market size is expected to reach USD 13.77 billion by 2030 registering a CAGR of 6.4% from 2023 to 2030.
  • Studies suggest that in 2020 the number of diabetic retinopathy cases were about 103.12 million; the cases are expected to reach 160.5 million by 2045.
  • Moreover, the increasing geriatric population in both developed and developing nations is expected to propel the market over the forecast period.
  • However, now that the lockdown restrictions have been removed, the market is expected to grow at a significant rate.

Can you really 'address' annoying eye floaters with a supplement?

Retrieved on: 
Thursday, June 29, 2023
Retina, Glaucoma, Partnership, Diabetes, Solution, Glucose, 3D, Sleep, Eye, Vitrectomy, GP, Acupressure, Vegetable, LCD, Language, 2D, YAG, Patient, Vance DeGeneres, Opacity, Risk, Swelling, Water, Collagen, Clearer, Health, Fasting, Floater, Antioxidant, Carotenoid, Dietary supplement, Mineral wool, Health insurance

They are known as floaters or, more formally, muscae volitantes – Latin for flying flies.

Key Points: 
  • They are known as floaters or, more formally, muscae volitantes – Latin for flying flies.
  • A recent article in the Mirror, Eye floaters: What causes them and how to get rid of them naturally, claims to have a solution.
  • Despite the promise in the headline, Dr Brewer does not talk about getting rid of floaters.
  • With age, the vitreous – a clear, gel-like substance inside the eye – starts to thicken and shrink.
  • With age, it’s normal for the vitreous to pull away from the back of the eye, a process called posterior vitreous detachment, and this causes more floaters.

What about other solutions?

    • But this surgery poses risks to a person’s vision far more significant than the floaters themselves.
    • Zapping floaters with a laser (known as a YAG laser) is another option, but not all experts agree that this is safe.
    • But while slowing ageing in the eye would be great, it’s not proof that it will stop people from getting floaters.
    • You’re more likely to get floaters if you are shortsighted, had cataract surgery, or if you’ve had eye inflammation (swelling).

The verdict

    • Can supplements and lifestyle changes slow the ageing process in the eye, delaying the onset of these age-related floaters?
    • Dr Brewer makes excellent recommendations about nutritious food, hydration and sleep – all great ways to maintain your health.

Two Tampa General Hospital Surgery Centers Named to Newsweek's Best List for 2023

Retrieved on: 
Friday, November 11, 2022
General surgery, Fast Track, Adult, Medicare, Ambulatory Surgery Center Association, Goal, Round Top hospitals, 3D ultrasound, Facility, Colorectal surgery, Tampa General Hospital, Gastroenterology, Ageing, Ophthalmology, Safety, Association, Accreditation, Hospital, COVID-19, News, ASC, Intensive care unit, Biopsy, Endoscopy, Urology, Patient, TGH, Center, GE Healthcare, FFS, Health, AAAHC, Vitrectomy, U.S. News & World Report, Woman, Tower, Colonoscopy, Neuroscience, Home, Forbes, Pain management, State, Trauma, Statista, Medicine, Dentistry, Birth control, Podiatry, Newsweek

TAMPA, Fla., Nov. 11, 2022 /PRNewswire/ -- The Surgery Center at Tampa General Hospital (TGH) Brandon Healthplex at 10740 Palm River Road in Tampa and the TGH Surgery Center at Morsani at 13330 USF Laurel Drive have been named to Newsweek's list of Best Ambulatory Surgery Centers for 2023. This marks the third consecutive year that both centers are on the list (the Center at Morsani was included in 2021 under its former name, the USF Ambulatory Surgery Center).

Key Points: 
  • The Best Ambulatory Surgery Centers 2023 list highlights the nation's top ambulatory surgery centers based on the quality of care, performance data, and peer recommendations.
  • TAMPA, Fla., Nov. 11, 2022 /PRNewswire/ -- The Surgery Center at Tampa General Hospital (TGH)Brandon Healthplex at 10740 Palm River Road in Tampa and the TGH Surgery Center at Morsani at 13330 USF Laurel Drive have been named to Newsweek's list of Best Ambulatory Surgery Centers for 2023 .
  • The ASC offers:
    "We are pleased to be recognized by Newsweek again as one of the best Ambulatory Surgery Centers for 2023," said Adam Smith, executive vice president and chief ambulatory officer with Tampa General Hospital.
  • To compile the Ambulatory Surgery Centers 2023 list, Newsweek worked with data research firm Statista to analyze more than 5,000 ambulatory surgery centers in 25 states.

Global Vitrectomy Devices Market Research Report to 2027 - Featuring Alcon, Blink Medical, Carl Zeiss Meditech and Hoya Surgical Optics Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
Growth, Investment, CAGR, Value, Business Growth Fund, Certification, COVID-19, Use, Decision-making, USD, Acquisition, R, Customer support, Technology, Vitrectomy, Strategic management, Market share analysis, Retail, Fine chemical

What are the inhibiting factors and impact of COVID-19 shaping the Global Vitrectomy Devices Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Vitrectomy Devices Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Vitrectomy Devices Market?
  • What is the market share of the leading vendors in the Global Vitrectomy Devices Market?
  • What modes and strategic moves are considered suitable for entering the Global Vitrectomy Devices Market?

Vitrectomy Machines Market to Surpass US$ 610 Million by 2027 Amid Rising Prevalence of Eye Disorders and Injuries

Retrieved on: 
Friday, November 4, 2022
Ivanti, Eye, Awareness, Growth, Vitrectomy, Hospital, Retinal detachment, Diabetic retinopathy, CAGR, Visual impairment, EVA, Government, Projection, Incidence, Needle, Trauma, Leica, Physician, Environment, Prevalence, Partnership, Diabetes, Renewable energy, Alcon

ROCKVILLE, Md., Nov. 4, 2022 /PRNewswire/ -- The global vitrectomy machines market is estimated to reach US$ 430 million in 2022 and further expand at 7.2% CAGR between 2022 and 2027. Sales in the market are expected to surpass a total valuation of US$ 610 Million by the end of 2027.

Key Points: 
  • Sales in the market are expected to surpass a total valuation of US$ 610 Million by the end of 2027 .
  • Rising incidence of eye injuries, retinal illnesses, and diabetes is providing a major impetus to the growth of vitrectomy machines market and the trend is likely to continue during the forecast period.
  • The rising frequency of ocular disorders, technical improvements in vitrectomy devices, and expanding government initiatives to raise awareness about visual impairment are expected to boost the vitrectomy machines market during the forecast period.
  • Innovative vitrectomy devices with several features are being developed by the key players in vitrectomy machines market to treat eye diseases.

Global Diabetic Retinopathy Market Report 2022: Featuring Alimera Sciences, Pfizer, Genentech, Bayer, Lumenis & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022
Diabetes, Health, Optical, Diabetic retinopathy, Growth, Blood, Fluocinolone acetonide, Intraocular pressure, Alimera Sciences, Risk, Eye, Injection, Macular edema, Vitrectomy, FDA, Patient, Prevalence, Severe cognitive impairment, Ranibizumab, Diabetes, Diagnosis, Pharmaceutical industry, Bevacizumab

Anticipated increase in prevalence of diabetes prevalence indicates that diabetic retinopathy will continue to the prevalence of vision loss in the future.

Key Points: 
  • Anticipated increase in prevalence of diabetes prevalence indicates that diabetic retinopathy will continue to the prevalence of vision loss in the future.
  • Estimates also suggest that diabetic retinopathy alone contributes 10% to 42% of direct medical costs, whereas the indirect costs could be much higher.
  • This report studies the global and regional markets for various diabetic retinopathy treatments currently available.
  • Despite the proven efficacy of vitrectomy in diabetic retinopathy management, late diagnosis of condition holds back the growth of this market.